[E-Daily Starin Choi Hee-jae Reporter] Actor Won Tae-min left a strong impression with his performance as the “red-haired” villain in the drama “Manager Kim.” Screenshot from the drama “Manager Kim” (Photo = SBS) Won Tae-min made a special appearance as Shin Seong-ho in the third episode of the SBS Friday-Saturday drama “Director Kim,” leaving a strong impression. Shin Seong-ho (played by Won Tae-min) is a character Director Kim (played by So Ji-sub) encounters while searching for his kidnapped daughter, Min-ji (played by Seo Su-min). Shin Seong-ho held Min-ji’s cell phone and taunted Director Kim, heightening the drama’s tension. To portray Shin Seong-ho—a character who stirs up conflict in the drama—in a multi-dimensional way, Won Tae-min underwent a striking visual transformation, including a red bridge hairstyle and tattoos. Acting as a “scene-stealer” who heightened the drama’s immersion, Won Tae-min earned praise not only for his unique presence but also for his intense on-screen chemistry with actor So Ji-sub. Episode 3 of “Director Kim,” featuring Won Tae-min, is gaining popularity, recording an 18.8% rating nationwide based on household viewership according to Nielsen Korea. Won Tae-min made his debut in the 2020 drama “Your Heart Is Muted.” Since then, he has appeared in “Why Oh Soo-jae?”, “Adamant,” “Unintentional Love Story,” and “Queenmaker.” He has been active in a wide range of acting projects, from musicals such as “If I Will You,” “Spy,” “Fan Letter,” and “Black Mary Poppins” to plays like “Anna X” and “Bbangya.” Won Tae-min is currently appearing in the musical “In Praise of Death.”
This week (November 16–20), startups in various fields—including robotics, image analysis, and business platforms—secured investments from venture capital (VC) firms and accelerators (ACs). In particu…
Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of t…
South Korean pharmaceutical and biotechnology stocks posted mixed results on November 19, driven by clinical trial developments and expectations regarding their inclusion in major stock indices. Penet…